STOCK TITAN

Ginkgo Bioworks Announces Participation in Upcoming Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

BOSTON, Nov. 24, 2021 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that management is scheduled to participate in the following upcoming conferences:

  • Piper Sandler Annual Healthcare Conference on Tuesday, November 30, 2021
  • Jefferies Alternative Protein & Related ESG Summit on Wednesday, December 1, 2021 at 6:30 p.m. ET
  • Goldman Sachs Byte-ology: The Convergence of Biotechnology and Technology Conference  on Thursday, December 9, 2021 at 11:00 a.m. ET

Further details, webcast links, and replays of the presentations where available will be posted on the company's investor relations website at https://investors.ginkgobioworks.com/events.

About Ginkgo Bioworks

Ginkgo is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo has also actively supported a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization, and therapeutics discovery. For more information, visit www.ginkgobioworks.com.

Ginkgo Bioworks Contacts:

INVESTOR CONTACT:
investors@ginkgobioworks.com   

MEDIA CONTACT:
press@ginkgobioworks.com  

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-announces-participation-in-upcoming-conferences-301431387.html

SOURCE Ginkgo Bioworks

Ginkgo Bioworks Holdings Inc

NYSE:DNA

DNA Rankings

DNA Latest News

DNA Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link

About DNA

the organism company ginkgo bioworks engineers new organisms to solve challenges across a range of industries from fuels to pharmaceutical production. our biological engineers make use of an in-house pipeline of synthetic biology technologies to design, build, and test new organisms.